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Sphingosine-1 phosphate receptorSphingosine kinases (SphKs) and their product sphingosine-1-phosphate (S1P) have been reported to regulate
apoptosis and survival of liver cells. Cholestatic liver diseases are characterized by cytotoxic levels of bile salts in-
ducing liver injury. It is unknown whether SphKs and/or S1P play a role in this pathogenic process. Here, we in-
vestigated the putative involvement of SphK1 and S1P in bile salt-induced cell death in hepatocytes. Primary rat
hepatocytes were exposed to glycochenodeoxycholic acid (GCDCA) to induce apoptosis. GCDCA-exposed hepa-
tocytes were co-treated with S1P, the SphK1 inhibitor Ski-II and/or speciﬁc antagonists of S1P receptors (S1PR1
and S1PR2). Apoptosis and necrosis were quantiﬁed. Ski-II signiﬁcantly reduced GCDCA-induced apoptosis in
hepatocytes (−70%, P b 0.05) without inducing necrosis. GCDCA increased the S1P levels in hepatocytes
(P b 0.05). GCDCA induced [Ca2+] oscillations in hepatocytes and co-treatment with the [Ca2+] chelator
BAPTA repressed GCDCA-induced apoptosis. Ski-II inhibited the GCDCA-induced intracellular [Ca2+] oscillations.
Transcripts of all ﬁve S1P receptors were detected in hepatocytes, of which S1PR1 and S1PR2 appear most dom-
inant. Inhibition of S1PR1, but not S1PR2, reduced GCDCA-induced apoptosis by 20%. Exogenous S1P also signif-
icantly reduced GCDCA-induced apoptosis (−50%, P b 0.05), however, in contrast to the GCDCA-induced
(intracellular) SphK1 pathway, this was dependent on S1PR2 and not S1PR1. Our results indicate that SphK1
plays a pivotal role inmediating bile salt-induced apoptosis in hepatocytes in part by interfering with intracellu-
lar [Ca2+] signaling and activation of S1PR1.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Sphingosine kinases (SphK1 and SphK2) are a distinct class of lipid
kinases that are rapidly activated by a variety of extracellular and/or
intracellular stimuli and are implicated in modulating cell survival
and apoptosis [1]. Additionally, activation of SphKs results in activation
of inﬂammatory processes, including generation of inﬂammatory cyto-
kines and reactive oxygen species [2–4]. SphKs catalyze phosphorylationery and Liver Transplantation,
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l rights reserved.of sphingosine to generate sphingosine 1-phosphate (S1P) [5,6]. Inter-
estingly, S1P has been reported to trigger both survival and apoptotic sig-
nals in different cell types [5,7–13]. S1P acts as a ﬁrst messenger through
the G protein coupled receptors (GPCRs), termed S1PR1, S1PR2, S1PR3,
S1PR4 and S1PR5, which are differentially expressed in different tissues.
The cell type-speciﬁc expression of S1P receptors (S1PRs), as well as
their differential coupling to different G-proteins, provides a clue to the
different functions of S1P [13]. Additionally, S1P can act as a secondmes-
senger in various cell types by activating calciumchannels and increasing
intracellular [Ca2+], thereby regulating cell proliferation, growth, migra-
tion and apoptosis [13,14].
In chronic (cholestatic) liver diseases, the liver is exposed to in-
creased levels of bile salts, cytokines and reactive oxygen species, all
of which independently can lead to loss of functional liver mass due
to hepatocyte cell death. Concomitantly, activated hepatic stellate cells
start proliferating and produce excessive amounts of extracellular ma-
trix proteins leading to liver ﬁbrosis, which may progress to end-stage
liver disease [15]. Hence, identifying the mechanisms of hepatocyte
Table 1
Sequences of primers and probes used for quantitative PCR analysis.
18S
rat
Sense
Antisense
Probe
5′-CGGCTACCACATCCAAGGA-3′
5′-CCAATTACAGGGCCTCGAAA-3′
5′FAM-CGCGCAAATTACCCACTCCCGA-TAMRA3′
S1P-r 1
rat
Sense
Antisense
Probe
5′-GCGGACGCAGCTTCGTC-3′
5′-CAGCAAGCAATCCGATGCTT-3′
5′FAM-CTCCGAGAAACAGCAGCCTCGCTCA-TAMRA3′
S1P-r 2
rat
Sense
Antisense
Probe
5′-CGGCCTAGCCAGTGCTCA-3′
5′-CGTCTCCTTGGTGTAATTGTAGTGTT-3′
5′FAM-CCGGCCACTGAGCCCCACCAT-TAMRA3′
S1P-r 3
rat
Sense
Antisense
Probe
5′-GCATGCAACCAGCCCAGAT-3′
5′-CGCCAGGAACGTTCATTTCAG-3′
5′FAM-CTGCACGCCTTCAGGAACCCACC-TAMRA3′
S1P-r 4
rat
Sense
Antisense
Probe
5′-TGCTCTTTTGTGTGGTGGTCTT-3′
5′-GTTGGCTCGGACCACCCTA-3′
5′FAM-CTATCCTGAGCCTCTACGGGGCCATC-TAMRA3′
S1P-r 5
rat
Sense
Antisense
Probe
5′-TACGCCAAGGCCTATGTGCT-3′
5′-CACCTGACAGTAAATCCTTGCATAGA-3′
5′FAM-CCTTCCTGGGCATCCTGGCTGC-TAMRA3′
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hepatocyte apoptosis. We have previously shown that the sodium-
taurocholate cotransporting polypeptide (NTCP) is crucial for conju-
gated bile salt-induced hepatocyte apoptosis [16], suggesting that
bile salt-induced intracellular signaling pathways play important roles
in modulating hepatocyte apoptosis. Additionally, it has been shown
that bile salt-induced apoptosis is a mitochondria-dependent process
which coincides with increased intracellular [Ca2+] levels [17]. Interest-
ingly, it has been suggested that SphK2 inhibition improvesmitochondri-
al function and hepatocyte survival after hepatic ischemia–reperfusion
[18]. However, the role played by SphK1 in hepatocyte apoptosis is cur-
rently unclear. In the present study, we have investigated the role played
by SphK1 in two models of bile salt- and cytokine-induced apoptosis in
rat hepatocytes.We demonstrate that SphK1 plays a pivotal role inmedi-
ating bile salt-induced apoptosis in hepatocytes, but this kinase has no
effect in cytokine-induced apoptosis. Additionally, we investigated the
effect of SphK1 inhibition on bile salt-induced intracellular [Ca2+]
mobilization.
2. Materials and methods
2.1. Animals
Speciﬁed pathogen-free male Wistar rats (220–250 g) were pur-
chased from Charles River Laboratories Inc. (Wilmington, MA, USA).
Animalswere kept under standard laboratory conditionswith free access
to standard laboratory chow andwater. All experimentswere performed
in accordance with the guidelines of the local Committee for Care and
Use of laboratory animals.
2.2. Experimental design
Hepatocytes were isolated and cultured in William's E medium in
a humidiﬁed incubator at 37 °C and 5% CO2 as described before [19].
Experiments were started after the attachment period of 4 h. In
order to induce apoptosis, monolayers of cultured primary hepatocytes
were exposed to 50 μM GCDCA (Sigma-Aldrich, St Louis, MO, USA) for
4 h or 20 ng/ml recombinant murine TNFα (R&D Systems, Abingdon,
U K) for 16 h. Where indicated, hepatocytes were treated with
10 μmol/L S1P (Sigma-Aldrich) prior to the exposure to the apopto-
tic stimulus. The following speciﬁc inhibitors were used: Ski II
(Tocris Biosciences, Bristol, UK) inhibitor of SphK1 (1–10 μM),
VPC23019 (Tocris Biosciences) antagonist of S1PR1 (5 or 10 μM),
JTE-013 (Tocris Biosciences) antagonist of S1PR2 (5 or 10 μM),
U0126 (Promega, Madison, USA) inhibitor of ERK1/2 (10 μM), SB
203580 (VWR, Amsterdam, The Netherlands) inhibitor of p38
MAPK (10 μM), LY 294002 (VWR) inhibitor of PI3 kinase (50 μM),
calphostin-C and bisindolylmaleimide I (BSM-I) (VWR) inhibitors
of protein kinase-C (1 μM), and actinomycin-D (Roche Diagnostics,
Almere, The Netherlands) transcriptional inhibitor (200 ng/ml). All
inhibitors and receptor antagonists were added to the cultured hepato-
cytes 30 min prior to the apoptotic stimuli unless stated otherwise. The
intracellular [Ca2+] chelator, BAPTA (25 μM, Sigma-Aldrich), was added
30 min prior to GCDCA. Hepatocytes cultured in HBSS (containing
Ca2+/Mg2+) instead of William's E medium were used as an internal
control in these experiments. All experiments were performed in tripli-
cate and each experimentwas repeated at least three times using hepa-
tocytes from different rats. Cells were harvested at the indicated time
points as described previously [16].
2.3. Apoptosis assay
Caspase-3 activity was measured as described previously [16]. The
arbitrary ﬂuorescence unit (AFU) was corrected for total protein con-
tent. Protein concentrationwas determined using a commercially avail-
able kit (Bio-Rad, Veenendaal, The Netherlands).2.4. Quantiﬁcation of lipids
After incubation the cells were immediately scraped, centrifuged
and re-suspended inmethanol to stop any enzymatic activity. Equal vol-
umes of the re-suspended pellet were processed for either sphingolipid
or phospholipid determination.
For the extraction of sphingolipids a mixture of iso-propanol:
water:ethyl acetate in the ratio 30:10:60 was added to the cell pellet.
After sonication and centrifugation the supernatant was transferred
to another tube, the pellet was re-extracted and the supernatants
were combined and dried. The extracted sphingolipids were analyzed
by liquid chromatography-electrospray tandem mass spectrometry
(LC-ESI-MS/MS) on a PE-Sciex API 3000 triple quadrupole mass spec-
trometer equippedwith a turbo ionspray source as describedpreviously
[20,21]. HPLC separation was performed as described previously [22],
with the following changes: an Alltima C-18 column (2.1 × 150 mm,
5 μm; Grace Davison Discovery Sciences) was used at a ﬂow rate of
200 μl/min. N2 was used as the nebulizing gas and drying gas for the
turbo ionspray source. The ion spray needle was held at 5500 V; the or-
iﬁce temperature was set to 500 °C. N2 was used to collisionally induce
dissociations in Q2. Multiple reaction monitoring scans were acquired
by setting Q1 and Q3 to pass the precursor and product ions of the
most abundant sphingolipid molecular species. MRM transitions were
optimized for each individual component (C-17SoP: 366.2/250.4;
C-17SaP: 368.2/270.4; C-18SoP: 380.2/264.4; C-18SaP: 382.2/284.4;
C-17So: 286.2/238.1; C-17Sa: 288.2/240.1; C-18So: 300.2/252.3;
C18Sa: 302.2/254.2). Quantitation was achieved by spiking the sam-
ples before extraction with sphingosine (d17:1), sphinganine (d17:0),
sphingosine-1-phosphate (d17:1), and sphinganine-1-phosphate
(d17:0) (Avanti Polar Lipids).
To determine the phospholipid content the lipids were extracted
from the cell pellet [23] and the phosphorus content, as a measure for
the phospholipid content, was determined using a phosphate assay
[24].
2.5. Quantitative PCR
RNA isolation, reverse transcription and quantitative real-time PCR
(qPCR)were performed as described previously [25] andmRNA expres-
sion levels were calculated relative to the housekeeping gene 18S.
Primers and probes are listed in Table 1.
2.6. Determination of intracellular [Ca2+] changes in hepatocytes
Freshly isolated hepatocytes were loaded with the Ca2+-probe
Fura2 (3 μM, Molecular Probes, USA) and Ca2+ imaging experiments
were performed 1 h after plating as described previously [26].
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Results are presented as the mean of at least 3 independent exper-
iments ± SD. Two way ANOVA was used to determine signiﬁcance of
differences between experimental groups. A P-value of less than 0.05
(P b 0.05) was considered statistically signiﬁcant.3. Results
3.1. Sphingosine kinase-1 inhibition protects hepatocytes against
GCDCA-induced apoptosis, but has no effect on TNFα/ActD-induced
apoptosis
GCDCA (at 50 μM) and TNFα/ActD induce caspase-3 activity in
primary rat hepatocytes that peaks after 4 h- and 16 h-exposure, re-
spectively [16]. Therefore, the effect of Ski II, a selective inhibitor of
SphK1 [27], on GCDCA- and TNFα/ActD-induced caspase-3 activity
was investigated at these time points. Ski II signiﬁcantly inhibited
the GCDCA-induced caspase-3 activity up to 70% (P b 0.05), in a
concentration-dependent manner (Fig. 1A). Exposure of primary rat
hepatocytes to Ski II (1–10 μM) alone did not induce caspase-3 activ-
ity, nor did it reduce the caspase-3 activity in TNFα/ActD-treated rat
hepatocytes (Fig. 1A and B). Since no toxic effects of Ski II were observed
at the highest concentration used, a concentration of 10 μMwas used for
all subsequent experiments. These data show that inhibition of SphK1
speciﬁcally protects primary rat hepatocytes against GCDCA-induced
apoptosis indicating that SphK1 activity is pro-apoptotic in these
cells.Fig. 1. Sphingosine kinase-1 (SphK1) inhibitor (Ski II) inhibits glycochenodeoxycholic acid
sphingosine-1-phosphate (S1P) level in hepatocytes. (A) Primary rat hepatocytes were tre
was added 30 min prior to the addition of GCDCA. *P b 0.05 for GCDCA + Ski II vs. GCDCA alone
of Ski II or a combination of both. Ski II was added 30 min prior to the addition of TNFα/ActD. (C
the addition of GCDCA (50 μM). *P b 0.05 for GCDCA vs. control at 10 min time point.3.2. GCDCA increases the intracellular level of S1P in rat hepatocytes
To investigate whether GCDCA-induced SphK1 activation increases
the intracellular S1P (the product of SphK1) level, we measured the
levels of S1P and sphingosine (the precursor of S1P) at several time
points after the addition of GCDCA to hepatocytes. Our data indicated
that GCDCA (at 50 μM) signiﬁcantly increased the level of S1P in primary
rat hepatocytes which peaked at 10 min-exposure (P b 0.05; Fig. 1C). In
addition, we observed a decrease in the sphingosine levels at the same
time point after the addition of GCDCA (although the difference in the
level of sphingosine was not statistically signiﬁcant; Fig. 1D). These
data strongly indicate that GCDCA-induced activation of SphK1 increases
the intracellular S1P level.3.3. The anti-apoptotic effect of SphK1 inhibition is independent of the
activation of ERK1/2, p38 MAP kinase, PI3-kinase, protein kinase C and
gene transcription
To investigate whether speciﬁc kinase pathways are involved in the
anti-apoptotic effects of Ski II, GCDCA-exposed rat hepatocytes were
co-treated with inhibitors of MAPK, PI3K or PKC. These inhibitors alone
did not induce caspase-3 activity in rat hepatocytes (data not shown)
nor did they induce caspase-3 activity in hepatocytes co-treated
with Ski II (Fig. 2). Importantly, the protective effect of Ski II against
GCDCA-induced caspase-3 activation was not abolished by inhibi-
tion of ERK1/2, p38 MAPK, PI3K and PKC (Fig. 2), suggesting that
the anti-apoptotic effect of Ski II is essentially independent of the activa-
tion of these kinase pathways. These inhibitors at the concentrations(GCDCA)-induced apoptosis in rat hepatocytes and GCDCA increases the intracellular
ated for 4 h with 50 μM of GCDCA, 1–10 μM of Ski II or a combination of both. Ski II
. (B) Hepatocytes were treated for 16 h with TNFα (20 ng/ml)/ActD (200 ng/ml), 1–10 μM
) S1P and (D) sphingosine were measured in lipid extracts of hepatocytes at 1–30 min after
Fig. 2. The protective effect of sphingosine kinase-1 inhibitor (Ski II) against glycochenodeoxycholic acid (GCDCA)-induced apoptosis is not dependent on the activation of p38 MAP
kinase, ERK1/2 MAPK, PI3K pathway, PKC pathway and gene transcription. Caspase-3 activity in rat hepatocytes treated with 50 μM of GCDCA in the presence and absence of Ski II
(10 μM) and with or without the inhibitors of ERK1/2-MAPK (10 μM of U0126; U0), p38 MAPK (10 μM of SB 203580; SB), PI3K (50 μM of LY 294002; LY), PKC inhibitors (1 μM of
calphostin-C and BSM-I), and transcription inhibitor (200 ng/ml of ActD). *P b 0.05 for GCDCA + Ski II vs. GCDCA. The differences between gray and white bars are not signiﬁcant.
1925G. Karimian et al. / Biochimica et Biophysica Acta 1832 (2013) 1922–1929tested here were effective in our positive control experiments [19].
In addition, we studied the role of gene transcription in the protec-
tive effect of Ski II against GCDCA-induced apoptosis. Actinomycin
D (200 ng/ml) is an inhibitor of gene transcription and sensitizes he-
patocytes to TNFα-induced apoptosis, but has no effect on GCDCA-
induced caspase-3 activity in rat hepatocytes ([16] and our data).
In addition, ActD treatment did not abolish the protective effect of
Ski II against GCDCA-induced caspase-3 activation (Fig. 2). This ﬁnd-
ing suggests that adaptive gene regulation is not required for the
anti-apoptotic effect of Ski II against GCDCA-induced apoptosis.3.4. GCDCA-induced apoptosis is dependent onmobilization of intracellular
[Ca2+] and SphK1 inhibition blunts GCDCA-induced [Ca2+] oscillations in
rat hepatocytes
It was previously shown that GCDCA-induced apoptosis coincides
with intracellular [Ca2+] mobilization from the ER, caspase-12 acti-
vation and mitochondrial dysfunction resulting in leakage of cyto-
chrome c [17], suggesting that intracellular [Ca2+] mobilization
contributes to GCDCA-induced apoptosis. We investigated the effect
of BAPTA (25 μM), a chelator of intracellular [Ca2+], on apoptosis in
GCDCA-exposed hepatocytes. BAPTA did not increase caspase-3 ac-
tivity in hepatocytes when added alone (Fig. 3A). Importantly, the
GCDCA-induced caspase-3 activity was signiﬁcantly reduced in
BAPTA loaded hepatocytes (−50%, P b 0.05), conﬁrming that the
mobilization of intracellular [Ca2+] pools plays an important role in
GCDCA-induced apoptotic signaling. The same results were obtained
when hepatocytes cultured in HBSS (containing Ca2+/Mg2+), serving
as controls for experiments performed in Williams' E medium, were
analyzed (Fig. 3A). We investigated the pattern of intracellular [Ca2+]
mobilization in GCDCA-exposed fura2-loaded hepatocytes and the ef-
fect of SphK1 inhibition on this intracellular [Ca2+] mobilization. Our
data showed that GCDCA (at 300 μM) in the presence of extracellular
[Ca2+], induces [Ca2+] oscillations in rat hepatocytes starting about 2–
8 min after the addition of GCDCA (Fig. 3B). Incubation with 300 μM
GCDCA did not induce necrosis in hepatocytes up to at least 1 h (data
not shown). We did not observe [Ca2+] oscillations with concentration
below 300 μMGCDCA, likely due to the experimental limitations. Inter-
estingly, the [Ca2+] oscillations induced by GCDCAwere not coordinat-
ed in hepatocytes nor were they homogenously induced in all cells at
the same time (Fig. 3B) unlike [Ca2+] oscillations induced by angioten-
sin II (Section 3.5). Importantly, these GCDCA-induced [Ca2+] oscilla-
tions were blunted or less frequent in the presence of Ski II (10 μM) in65% of hepatocytes, which showed [Ca2+] oscillations induced by
GCDCA (Fig. 3C), suggesting that GCDCA-induced [Ca2+] oscilla-
tions in these hepatocytes are mediated via S1P produced by
SphK1. When added alone, Ski II did not induce calcium oscillations
(data not shown). In addition, Ski II had the same inhibitory effect
on taurolithocholic-sulfate (TLCS)-induced [Ca2+] oscillations in
hepatocytes (Supplementary data), suggesting that the inhibitory
effect of Ski II on cholestatic bile salt-induced [Ca2+] oscillations
is not limited to GCDCA.3.5. S1PR1-dependent signaling contributes to the pro-apoptotic effect of
GCDCA while exogenous S1P protects hepatocytes against GCDCA-induced
apoptosis via interaction with S1PR2
S1P acts as a ﬁrst messenger via its receptors, S1PR1–5 [13]. We
detected signiﬁcant mRNA expression levels of all S1P receptors in rat
hepatocytes (Fig. 4A). S1PR1 and S1PR2 were expressed more abun-
dantly compared to the others, which is in accordance with a previous
report [28]. We investigated the effect of inhibiting S1PR1 and S1PR2
on GCDCA-induced apoptosis using speciﬁc antagonists of S1PR1
(VPC23019, at 5 and 10 μM) and S1PR2 (JTE-013, at 5 and 10 μM), re-
spectively. None of these S1P receptor antagonists induced caspase-3
activation when added to hepatocytes alone (Fig. 4B). The apoptotic
effect of GCDCAwas reduced signiﬁcantly (−20%, P b 0.05) in the pres-
ence of S1PR1 antagonist, indicating that S1PR1-dependent signaling
contributes to the pro-apoptotic effect of GCDCA (Fig. 4B). By contrast,
the S1PR2 antagonist did not signiﬁcantly inhibit GCDCA-induced
caspase-3 activity, suggesting that GCDCA-induced apoptosis is not
mediated via S1PR2-dependent signaling. In fact, hepatocytes may
become even more sensitive to the toxic effect of GCDCA in the pres-
ence of the S1PR2 antagonist (Fig. 4B).
Endogenous S1P can induce intracellular signaling pathways inde-
pendent of S1P receptors and/or via interaction with S1P receptors
while exogenous S1P interacts with S1P receptors. Therefore, different
functions can be expected from endogenous S1P and exogenous S1P
[8,13,29]. Consequently, we also investigated the effect of exogenous
S1P (10 μM) on GCDCA-induced apoptosis in hepatocytes. The concen-
tration of exogenous S1P (100 nM–10 μM) that causes various responses
in cells is comparablewith the plasma and tissue concentrations of S1P in
vivo [29–32]. When added alone, S1P (10 μM) did not induce caspase-3
activation in rat hepatocytes, but signiﬁcantly inhibited GCDCA-induced
caspase-3 activity (−50%, P b 0.05; Fig. 4C). Interestingly, the protective
effect of exogenous S1P against GCDCA-induced apoptosis was reversed
Fig. 3. Glycochenodeoxycholic acid (GCDCA)-induced apoptosis in rat hepatocytes is
dependent on the intracellular [Ca2+]mobilizations and sphingosine kinase-1 (SphK1) in-
hibition blunts GCDCA-induced [Ca2+] oscillations in rat hepatocytes. (A) Primary rat he-
patocytes were plated in the William's E medium (WE) or Hank's buffered salt solution
(HBSS) containing calcium and magnesium. Caspase-3 activity in rat hepatocytes treated
with GCDCA (50 μM) andwith orwithout BAPTA (25 μM). Hepatocyteswere loadedwith
BAPTA 30 min prior to the addition of GCDCA. *P b 0.05 for GCDCA + BAPTA vs. GCDCA
(in WE) and #P b 0.05 for GCDCA + BAPTA vs. GCDCA (in HBSS). (B) The ﬁgure shows
measurements of intracellular [Ca2+] oscillations in three representative hepatocytes
loaded with Fura2-AM. Cells were incubated with 300 μMGCDCA and [Ca2+] oscillations
weremeasured during 15–20 min. The trace shown is representative of those obtained in
at least three independent experiments. (C) The ﬁgure shows measurements of intracel-
lular [Ca2+] oscillation in two representative hepatocytes loaded with Fura2-AM. Cells
were ﬁrst perfused with 300 μM GCDCA (the left part of the graph in continuous line)
and then with GCDCA (300 μM) + Ski II (10 μM), successively (the gray box). Subse-
quently cells were re-perfused with GCDCA (the right part of the graph). The trace
shown is representative of those obtained in at least three independent experiments.
[Ca2+] oscillations were inhibited or less frequent upon perfusion with GCDCA + Ski II
in 65% of hepatocytes that were individually imaged. ATP (10 μM)was used as an internal
control, indicating that the cells were still responsive to stimulus.
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but not in hepatocytes co-treated with the S1PR1 antagonist (VPC23019,
10 μM; Fig. 4C). Exogenously added S1P (10 μM) did not induce [Ca2+]
oscillations in rat hepatocytes (Fig. 4D) and prevented GCDCA-induced
[Ca2+] oscillations. S1P did not lead to irreversible blockade of [Ca2+] os-
cillations as those could subsequently be induced by the positive control,
angiotensin II (AII, 10 nM; Fig. 4D). These data indicate that exogenous
S1P has anti-apoptotic effects in primary rat hepatocytes and acts via a
S1PR2-dependent signaling pathway.4. Discussion
In the present study, we show that pro-apoptotic GCDCA increases
the level of S1P in primary rat hepatocytes and that inhibition of
SphK1 reduces GCDCA-induced apoptosis. We further demonstrate
that the protective effect of Ski II occurs independently of various specif-
ic kinase pathways and of adaptive gene regulation. However, it is de-
pendent on the mobilization of intracellular [Ca2+] and Ski II inhibits
GCDCA-induced [Ca2+] oscillations. We suggest that S1PR1-dependent
signaling contributes to the pro-apoptotic effect of GCDCA. By contrast,
exogenous S1P promotes cell survival against GCDCA-induced apopto-
sis via S1PR2-dependent signaling in rat hepatocytes (see Graphical
abstract).
SphKs and S1P have been implicated to play a role in apoptosis and
survival of liver cells [1,8,18]. SphK2 activation leads to the mitochon-
drial dysfunction and hepatocyte apoptosis after hepatic ischemia–
reperfusion injury [18]. S1P may activate both apoptotic and survival
pathways at the same time and the balance between the two pathways
determine the result. For instance, S1P is pro-apoptotic in human hepatic
myoﬁbroblasts acting via a receptor-independent pathway, while con-
comitant signaling via S1P receptors is anti-apoptotic [8]. The effect of
SphK1 activation and S1P on hepatocyte apoptosis has not yet been elu-
cidated. Hepatocyte apoptosis in response to elevated levels of toxic
stimuli, such as bile salts, cytokines and reactive oxygen species, contrib-
utes to the pathogenesis of chronic liver diseases. Understanding the
mechanisms of hepatocyte injury is therefore of great relevance for the
development of therapeutic strategies to prevent hepatocyte apoptosis.
Therefore, we studied the role played by SphK1 and S1P in models of
bile salt (GCDCA)-induced and cytokine (TNFα)-induced hepatocyte ap-
optosis in vitro.
In our study, we have used Ski II to inhibit SphK1 signaling. Ski II is
a selective inhibitor of SphK1 that does not act on the ATP-binding
site of the enzyme and is highly speciﬁc for SphK1 up to 60 μM [27].
Using this strategy, our data indicate that GCDCA-induced apoptosis
is in part dependent on SphK1 signaling in rat hepatocytes. In addition,
we conﬁrmed that GCDCA induces a transient peak in intracellular S1P
level, which can act as a signaling lipid in apoptotic pathways. In con-
trast to a previous report [10], we demonstrate that TNFα-induced ap-
optosis in rat hepatocytes is not SphK1-dependent. Osawa et al. [10]
analyzed the role of SphKs in human hepatoma cell lines and used
non-selective (broad range) inhibitors (DMS and DHS) of SphKs. In
our study, we analyzed primary rat hepatocytes and focused on the
role of SphK1 by applying a highly selective inhibitor (Ski II). These ex-
perimental differences may explain the fact that we did not observe an
effect of inhibition of SphK1 on TNFα-induced apoptosis.
Endogenous S1P was shown to function as a powerful mediator of
[Ca2+] release through a non-InsP3 receptor-mediated mechanism in
the ER membrane [33,34]. Furthermore, it has been demonstrated
that UTP stimulates [Ca2+] mobilization in a SphK-dependent manner,
which is not mimicked by exogenous S1P [35]. Altogether, these reports
suggest that endogenous S1P generated by SphK activation induces intra-
cellular [Ca2+]mobilization. GCDCA-induced apoptosis in rat hepatocytes
has been shown to coincide with elevated intracellular [Ca2+] levels [17].
Accordingly, we show that GCDCA-induced apoptosis is dependent on in-
tracellular calciummobilization (since the GCDCA-induced apoptosiswas
reduced in hepatocytes loaded with the [Ca2+] chelator BAPTA). In our
experiments, the GCDCA-induced increase in [Ca2+] is coinciding with
[Ca2+] oscillations. Remarkably, not all hepatocytes showed [Ca2+] os-
cillations in response to bile salts and the [Ca2+] oscillations were not
coordinated in hepatocytes. It was previously shown that the lack of co-
ordination of [Ca2+] oscillations in hepatocytes can result either from
the absence of InsP3 production by bile salts or from the inhibitory effect
of bile salts on the permeability of gap junction channels [36,37]. Al-
thoughwe did not speciﬁcally test thesemechanisms, theymayprovide
a clue to explain the lack of homogeneity and coordination of [Ca2+] os-
cillations induced byGCDCA in our experiments. Interestingly, we show
Fig. 4. Sphingosine-1 phosphate receptor 1 (S1PR1)-dependent signaling contributes to pro-apoptotic effect of GCDCA but not sphingosine-1 phosphate receptor 2 (S1PR2), while
exogenous sphingosine-1 phosphate (S1P) protects hepatocytes against GCDCA-induced apoptosis via interaction with S1PR2. (A) Expression pattern of S1P receptors (S1P-r 1–5)
in rat hepatocytes. qPCR analysis for S1P receptors using cDNA of rat hepatocytes in primary cultures at 4 h after plating. (B) Hepatocytes were treated with 5 and 10 μM of S1PR1
antagonist (VPC23019) or S1PR2 antagonist (JTE-013) 30 min prior to the addition of GCDCA (50 μM). *P b 0.05 for GCDCA + VPC23019 vs. GCDCA. (C) Primary rat hepatocytes
were treated for 4 h with 50 μM of GCDCA with or without 10 μM of S1P in the medium. S1P2 antagonist (JTE-013, 10 μM) and S1P1 antagonist (VPC23019, 10 μM) were added
30 min prior to the addition of S1P. *P b 0.05 for GCDCA + S1P vs. GCDCA alone. (D) The upper ﬁgure shows measurements of intracellular [Ca2+] oscillation in three represen-
tative hepatocytes loaded with Fura2-AM. Cells were ﬁrst incubated with 10 μM S1P and then perfused with S1P (10 μM) + GCDCA (300 μM), successively. Subsequently cells
were washed and incubated with angiotensin II (AII, 10 nM), serving as a positive control, indicating that cells were still responsive to stimulus. The traces shown are representative
of those obtained in at least three independent experiments using individual rat hepatocytes.
1927G. Karimian et al. / Biochimica et Biophysica Acta 1832 (2013) 1922–1929that GCDCA induces [Ca2+] oscillations in a SphK1-dependent manner,
which is not mimicked by exogenous S1P at the concentration that is
anti-apoptotic in hepatocytes. It has previously been shown that exog-
enous S1P mobilizes intracellular [Ca2+] in rat hepatocytes [14,38],
but this did not present as [Ca2+] oscillations. Therefore, we suggest
that endogenous S1P generated by GCDCA-mediated pathways can act
as a second messenger to induce [Ca2+] oscillations in rat hepatocytes.
Inhibition of SphK1 activation inhibits GCDCA-induced apoptosis as
well as GCDCA-induced [Ca2+]i oscillations.
[Ca2+]i oscillations are implicated in the regulation of different
cellular processes in hepatocytes including glucose metabolism and
cell proliferation [39,40]. [Ca2+] oscillations are reported to regulate
transcriptional activity in cells [41,42] although our data indicate
that neither GCDCA-induced apoptosis [16] nor the protective action
of Ski II (present study) required adaptive gene regulation. Some cho-
lestatic bile salts have been shown to increase intracellular [Ca2+] and
induce [Ca2+] oscillations in rat hepatocytes [37,43]. In the present
study, we suggest that bile salt-induced [Ca2+] oscillations in rat hepa-
tocytes promote apoptosis; however, the exact pathway of the [Ca2+]
oscillation-induced events in regulating apoptosis remains unclear. It
is reported that TUDCA (a choleretic anti-apoptotic bile salt [16]) can
also induce [Ca2+] oscillations in the H4-IIE cell line [44]; however,
this ﬁnding could not be conﬁrmed in rat hepatocytes [37]. In addition,
it is reported that TUDCA plays an important role in maintainingintracellular calcium homeostasis by reducing thapsigargin-induced re-
lease of Ca2+ from ER stores, resulting in themaintenance of mitochon-
drial membrane potential and cell survival [45]. It is therefore highly
likely that cholestatic bile salt-induced [Ca2+] oscillations in rat hepato-
cytes constitute a pro-apoptotic signal in these cells.
Activation of MAP-kinase signaling, PI3-kinase signaling and PKC
signaling pathways in hepatocytes plays an important role in deter-
mining the balance between death and survival in response to stress
[16,46–49]. In addition, S1P and S1P receptors are reported to interact
with these kinases [8,10,28,50]. We hypothesized that the inhibition
of these kinases would re-sensitize Ski II treated hepatocytes to
GCDCA-induced apoptosis, but our data demonstrate that inhibition
of ERK, PI3-kinase and/or PKC pathways is not involved in the pro-
tective effect of Ski II.
In the present study, we observe opposing functions for exogenous
S1P versus endogenous S1P. Many reports indicate that S1P acts as a
ﬁrst messenger on cell surface S1P receptors in a paracrine and/or auto-
crine manner (reviewed in [51]). We suggest that in GCDCA-induced
apoptosis, themain autocrine and/or paracrine role of S1P as a ﬁrst mes-
senger is to activate S1PR2-dependent survival signaling. It has been
shown that in rat hepatocytes exogenous S1P can activate ERK1/2 and
Akt via interaction with S1PR2 [28]. Additionally, activation of ERK1/2
and Akt signaling pathways contributes to hepatocyte survival [16].
Activation of these pathways could contribute to the protective effect
1928 G. Karimian et al. / Biochimica et Biophysica Acta 1832 (2013) 1922–1929of exogenous S1P against GCDCA-induced apoptosis. Interestingly, the
GCDCA-induced activation of S1PR1-dependent signaling (likely by se-
creted endogenously generated S1P) is pro-apoptotic for rat hepato-
cytes; however, this pathway does not seem to play a major role in
GCDCA-induced apoptosis as the antagonist of S1PR1 reduced GCDCA-
induced apoptosis only by 20%. Therefore, our evidence that GCDCA-
induced apoptosis is a SphK1-dependent event indicates that the generat-
ed endogenous S1P acts as a secondmessenger to promote cell apoptosis
in rat hepatocytes. Therefore, inhibiting SphK1 in hepatocytes could be an
effective novel anti-apoptotic strategy in the treatment of cholestatic liver
disease.
In summary, the results of this study demonstrate that GCDCA in-
duces apoptosis in rat hepatocytes in a SphK1-dependent manner and
suggests that endogenously generated S1P act as a second messenger
to induce [Ca2+] oscillations and apoptosis in rat hepatocytes.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.06.011.
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